66

CLAIMS

1. An anti-estrogenic compound of the general formula I

5

15

20

30

40

Ι

wherein

A is a 8-22 atoms long substituent, which sub- 10 stituent A is defined by D_{1-6} , wherein D is chosen from the group comprising R4-C(O)R4, R4S(O)₀₋₂R4, N(R4)₃, R4OR4 and R4(C6H4)R4

wherein R4 independently represents a bond, or H, or a halogenated or non-halogenated, saturated or unsaturated, mono-, di-, or trivalent C1-C12 hydrocarbon

B',B'' are H,H or H,O-R3 or O-R3,H or H,F or together represent =O;

R1 is H, or a potentially metabolically unstable group chosen from the group comprising a straight, branched, or cyclic C1-C6 alkyl, C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl;

R2 is H, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl or benzoyl;

R3 is H, or C1-C3 alkyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl; and

X is methylene or a single bond, or pharmaceutically acceptable salts of the compounds of the general formula I.

2. A compound according to claim 1, wherein A is

 $-(CH_2)_{4-6}N((CH_2)_{0-2}H)(CH_2)_{2-4}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

3. A compound according to any of claims 1-2, wherein A is $-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

4. A compound according to any of claims 1-2, wherein A is

-(CH₂) $_{8-12}$ C(O)N((CH₂) $_{0-2}$ H)(CY₂) $_{2}$ - $_{6}$ Y wherein Y is chosen from H or F.

67

5. A compound according to any of claims 1-4, wherein R1 is hydrogen, or methyl, or acetyl, or benzoyl, or sulphamoyl, or N-acetyl-sulphamoyl.

- 5 6. A compound according to any of claims 1-5, wherein R3 is H, or methyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl.
- 10 7. A compound according to claim 1, wherein A is $-(CH_2)_{\,4-6}N\,((CH_2)_{\,0-2}H)\,(CH_2)_{\,2-4}S\,(O)_{\,0-2}\,(CH_2)_{\,2-4}\,(CF_2)_{\,1-3}CF_3$ or $-\,(CH_2)_{\,7-11}S\,(O)_{\,0-2}\,(CH_2)_{\,2-4}\,(CF_2)_{\,1-3}CF_3$
- 15 or $-(CH_2)_{8-12}C(O)N((CH_2)_{0-2}H)(CY_2)_{2}-_{6}Y$ wherein Y is chosen from H or F or $-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3$
- 20 or $-C_6H_4-p-O(CH_2)_{3-6}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$ or $-C_6H_4-p-O(CH_2)_{2}NMe_2;$

R1 is hydrogen, or methyl, or acetyl, or benzoyl, or 25 sulphamoyl, or N-acetyl-sulphamoyl;

R2 is hydrogen; and

R3 is H, or methyl, or a potentially metabolically unstable group chosen from the group comprising C1-C6 acyl, benzoyl, sulphamoyl, or N-acetyl-sulphamoyl.

8. A compound according to claim 1,
wherein A is

-(CH₂)₄₋₆N(CH₃)(CH₂)₂₋₄S(O)₀₋₂(CH₂)₂₋₄(CF₂)₁₋₃CF₃

or

35 $-(CH_2)_{7-11}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$

or

 $-\,(\text{CH}_2)_{\,10}\text{C}\,(\text{O})\,\text{N}\,(\text{CH}_3)\,(\text{CY}_2)_{\,2}-_6\text{Y}$ wherein Y is chosen from H or F

or $-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3;$

B',B'' are H,H or H,O-R3 or O-R3,H or H,F; R1 is H, or methyl, or acetyl, or sulphamoyl; and R3 is H, or methyl, or acyl;

9. A compound according to claims 1, wherein A is $-(CH_2)_{4-6}N(CH_3)(CH_2)_3S(O)_{0-2}(CH_2)_3CF_2CF_3$ or $-(CH_2)_{8-10}S(O)_{0-2}(CH_2)_{2-4}(CF_2)_{1-3}CF_3$ or

68

 $-(CH_2)_{8-9}CH(CO_2H)(CH_2)_{2-5}(CF_2)_{1-3}CF_3$ and R3 is H.

15

40

5 10. A compound according to any one of claims 1-9 chosen from the group comprising $11-(3,16\alpha-Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7\alpha-yl)-undecanoic acid n-butyl-methyl-amide,$

10 11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide 3-O-benzoate,

 $11-(3,16\alpha-Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7\alpha-yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,$

3,16 α -Dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,

3,16 α -Dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

3,16α-Dihydroxy-17-methylene-7α-[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-0-acetate,

3,16 α -Dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

35 3,16 α -Dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

3,16 α -Dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-penta-fluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,

 $7\alpha-[9-[(2,2,3,3,4,4,4-Heptafluoro-n-butyl)sulfinyl]nonyl]-3,16<math>\alpha$ -dihydroxy-17-methylene-estra-1,3,5(10)-triene,

3,16 α -Dihydroxy-17-methylene-7 α -[9-[(3,3,4,4,5,5,6,6,6-45 nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

69

3,16 α -Dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,

- 5 3,16 α -Dihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl-estra-1,3,5(10)-triene,
- 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-10 (4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]pentyl]-estra-1,3,5(10)-triene,
- 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,
 - 3,16 α -Dihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-benzoate,
- 3,16α-Dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

20

- 3,16 α -Dihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 3,16 α -Dihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-30 (4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- $11-(3,16\alpha-Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7\alpha-y1)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,$
 - 11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,
- 11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

70

10-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

- 5 11-(3,16 α -Dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -y1)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexy1)-undecanoic acid methylester,
- $2-[9-(3,16\alpha-Dihydroxy-17-methylene-estra-1,3,5(10)-10$ triene- 7α -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,
 - 11-(3,6 α ,16 α -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide,
- 15 3, 6α , 16α -Trihydroxy-17-methylene- 7α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,
- 3,6 α ,16 α -Trihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-20 pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,
- 3,6 α ,16 α -Trihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,

- 3,6 α ,16 α -Trihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 3,6 α ,16 α -Trihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl-estra-1,3,5(10)-triene 3-0-sulfamate,
- 35 3,6 α ,16 α -Trihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 3,6 α ,16 α -Trihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-40 (3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 11-(3,6 α ,16 α -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,

71

10-(3,6 α ,16 α -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,

5

- 11-(6 β -Fluoro-3,16 α -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide,
- 10 6β -Fluoro-3,16 α -dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,
 - 6β -Fluoro-3,16 α -dihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-

15 triene,

 6β -Fluoro-3,16 α -dihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

20

- 6β -Fluoro-3,16 α -dihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 25 6β-Fluoro-3,16α-dihydroxy-17-methylene-7α-[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 11-(6 β -Fluoro-3,16 α -dihydroxy-17-methylene-estra-30 1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,
- 10-(6 β -Fluoro-3,16 α -dihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-decanoic acid,
 - 3,6 β ,16 α -Trihydroxy-17-methylene-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

40

3,6 β ,16 α -Trihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

72

3,6 β ,16 α -Trihydroxy-17-methylene-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

- 5 11-(3,6 β ,16 α -Trihydroxy-17-methylene-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-undecanoic acid,
- 11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-10 triene-7 α -yl)-undecanoic acid n-butyl-methyl-amide,

- $11-(17-(1,2-Ethylene)-3,16\alpha-dihydroxy-estra-1,3,5(10)-triene-7\alpha-yl)-undecanoic acid n-butyl-methyl-amide 3-0-benzoate,$
- 11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4-hepta-fluoro)-n-butyl-methyl-amide,
- 20 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,
 - 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-0-acetate,
- 30 $17-(1,2-\text{Ethylene})-3,16\alpha-\text{dihydroxy}-7\alpha-[9-[(4,4,5,5,5-\text{pentafluoro-n-pentyl})\,\text{sulfinyl}]\text{nonyl}]-\text{estra-1},3,5(10)-\text{triene} 3-0-\text{sulfamate},$
- 35 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-40 pentafluoro-n-pentyl)sulfinyl]octyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-7 α -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl)sulfinyl]nonyl]-3,16 α -dihydroxy-estra-1,3,5(10)-triene,

73

- 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,
- 5 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl-estra-1,3,5(10)-triene,
- $17-(1,2-\text{Ethylene})-3,16\alpha-\text{dihydroxy}-7\alpha-[5-[N-\text{methyl-N-3-}(4,4,5,5,5-\text{pentafluoro-n-pentylthio})-\text{propylamino}]-\text{pentyl}]-$ estra-1,3,5(10)-triene 3-O-benzoate,
 - 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-0-acetate,
- $17-(1,2-Ethylene)-3,16\alpha-dihydroxy-7\alpha-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-0-sulfamate,$
- 25 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

20

- 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-30 (4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- $17-(1,2-Ethylene)-3,16\alpha-dihydroxy-7\alpha-[5-[N-methyl-N-3-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-propylamino]-$ 35 pentyl]-estra-1,3,5(10)-triene,
 - 17-(1,2-Ethylene)-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

74

11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid,

- 5 11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-4 undecanoic acid,
- 10-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-10 triene-7 α -yl)-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)decanoic acid,
- 11-(17-(1,2-Ethylene)-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(3,3,4,4,5,5,6,6-nonafluoro-n-hexyl)-undecanoic acid methylester,
 - $2-[9-(17-(1,2-Ethylene)-3,16\alpha-dihydroxy-estra-1,3,5(10)-triene-7\alpha-y1)-nony1]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,$
- 20 $11-(17-(1,2-Ethylene)-3,6\alpha,6\alpha-trihydroxy-estra-1,3,5(10)-triene-7\alpha-yl)-undecanoic acid n-butyl-methyl-amide,$
- 11-(17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-estra-1,3,5(10)-25 triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4-hepta-fluoro)-n-butyl-methyl-amide,
 - 17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,
- 30 $17-(1,2-Ethylene)-3,6\alpha,6\alpha-trihydroxy-7\alpha-[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,$
- 35 17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene 3-O-sulfamate,
- 17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-7 α -[9-[(4,4,5,5,5-9entafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-7 α -[9-[(2,2,3,3,4,4,4-heptafluoro-n-butyl) sulfinyl]nonyl]-3,6 α ,6 α -trihydroxy-estra-1,3,5(10)-triene,

75

17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

- 5 17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-O-sulfamate,
- 17-(1,2-Ethylene)-3,6α,6α-trihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

- 17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 11-(17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,
- 25 $10-(17-(1,2-\text{Ethylene})-3,6\alpha,6\alpha-\text{trihydroxy-estra-1},3,5(10)-\text{triene}-7\alpha-\text{yl})-2-(3,3,4,4,5,5,6,6,6-\text{nonafluoro-n-hexyl})-\text{decanoic acid,}$
- 11-(17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-estra-1,3,5(10)-30 triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)undecanoic acid methylester,
- 11-(17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,
 - 2-[9-(17-(1,2-Ethylene)-3,6 α ,6 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-nonyl]-2-(3,3,4,4,5,5,6,6,6-nonafluoro-n-hexyl)-malonic acid,
- 40 $11-(17-(1,2-Ethylene)-6\beta-fluoro-3,16\alpha-dihydroxy-estra-1,3,5(10)-triene-7\alpha-yl)-undecanoic acid n-butyl-methylamide,$

76

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-undecanoic acid (2,2,3,3,4,4,4-heptafluoro)-n-butyl-methyl-amide,

- 5 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[910 [(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra1,3,5(10)-triene,
- 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra1,3,5(10)-triene 3-O-sulfamte,
 - 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfonyl]nonyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,

- 25 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene 3-0-sulfamate,
- 17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-7 α -[5-[N-30 methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfinyl)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 17-(1,2-Ethylene)-6β-fluoro-3,16α-dihydroxy-7α-[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylsulfonyl)propylamino]-pentyl]-estra-1,3,5(10)-triene,
 - 11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,

77

11-(17-(1,2-Ethylene)-6 β -fluoro-3,16 α -dihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)-undecanoic acid methylester,

- 5 17-(1,2-Ethylene)-3,6 β ,6 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)thio]nonyl]-estra-1,3,5(10)-triene,
 - 17-(1,2-Ethylene)-3,6 β ,6 α -trihydroxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triono
- 10 triene,
 - 17-(1,2-Ethylene)-3,6 β ,6 α -trihydroxy-7 α -[5-[N-methyl-N-3-(4,4,5,5,5-pentafluoro-n-pentylthio)-propylamino]-pentyl]-estra-1,3,5(10)-triene,
- 20 11-(17-(1,2-Ethylene)-3,6 β ,6 α -trihydroxy-estra-1,3,5(10)-triene-7 α -yl)-2-(4,4,5,5,5-pentafluoro-n-pentyl)-undecanoic acid,
- 11-(17-(1,2-Ethylene)-3,6 β ,6 α -trihydroxy-estra-1,3,5(10)-25 triene-7 α -yl)-2-(4,4,5,5,6,6,7,7,7-nonafluoro-n-heptyl)undecanoic acid,
- $17-(1,2-\text{Ethylene})-3,16\alpha-\text{dihydroxy}-6-\text{keto}-7\alpha-[9-(4,4,5,5,5-\text{pentafluoro}-n-\text{pentyl})\text{thiononyl}]-estra-30 1,3,5(10)-triene,$
 - 17-(1,2-Ethylene)-3,16 α -dihydroxy-6-keto-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,
- 35 $17-(1,2-\text{Ethylene})-3,16\alpha-\text{dihydroxy}-6-\text{keto}-7\alpha-[5-[N-\text{methyl-N-3}-(4,4,5,5,5-\text{pentafluoro-n-pentylthio})-\text{propylamino}]-\text{pentyl}-\text{estra-1},3,5(10)-\text{triene},$
- 40 17-(1,2-Ethylene)-3,16 α -dihydroxy-6 α -methoxy-7 α -[9-(4,4,5,5,5-pentafluoro-n-pentyl)thiononyl]-estra-1,3,5(10)-triene,

78

17-(1,2-Ethylene)-3,16 α -dihydroxy-6 α -methoxy-7 α -[9-[(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra-1,3,5(10)-triene,

- 5 $17-(1,2-\text{Ethylene})-3,16\alpha-\text{dihydroxy}-6\beta-\text{methoxy}-7\alpha-[9-(4,4,5,5,5-\text{pentafluoro-n-pentyl})\text{thiononyl}]-estra-1,3,5(10)-triene, and$
- 17-(1,2-Ethylene)-3,16 α -dihydroxy-6 β -methoxy-7 α -[910 [(4,4,5,5,5-pentafluoro-n-pentyl)sulfinyl]nonyl]-estra1,3,5(10)-triene.
 - 11. An intermediate compound of the general formula VIII:

15

wherein R1, R2 and X are as defined in claim 1.

- 12. A compound according to any one of claims 1--10 for use as a medicament.
- 13. Use of a compound according to any one of claims 1-10 for the manufacturing of a medicament for the treatment of an estrogen related disorder or condition that benefits from antiestrogen treatment.
- 14. Use according to claim 13, wherein the estrogen related disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis,
- ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.
- 15. Use according to claim 13 or 14, wherein the estrogen related disorder is estrogen dependent breast cancer.

79

16. A pharmaceutical composition comprising a compound according to any one of claims 1-10, admixed with one or more pharmaceutically acceptable excipients or carriers.

- 5 17. A pharmaceutical composition according to claim 16, wherein the excipients are chosen from the group comprising filling agents, lubricants, flavours, colourings, sweetenings, buffers, acidifying agents, diluents and preservatives.
- 18. A pharmaceutical composition according to any one of claims 16-17, which is administered orally, intramuscularly, intravenously, intraperitoneally or subcutaneously, via implants, rectally, intranasally, transdermally, or vaginally; preferably orally, transdermally or intranasally.
- 19. A method of treatment comprising administration of a pharmaeutically effective amount of compound according to claim 1-10 or a pharmaceutical composition according to claim 16-17 to a subject suffering from an estrogen dependent disorder or condition.
- 20. A method of treatment according to claim 19, wherein the estrogen dependent disorder or condition is chosen from the group comprising estrogen dependent breast cancer, anovulatory infertility, menstrual disorders, male pattern baldness, dysfunctional uterine bleeding, endometrial polyps, benign breast disease, uterine leiomyomas, adenomyosis, ovarian cancer, endometrial cancer, melanoma, prostate cancer, cancers of the colon, CNS cancers, endometriosis, polycystic ovary syndrome, infertility and contraception in males.
- 35 21. A method of treatment according to claim 19 or 20, wherein the estrogen dependent disorder is estrogen dependent breast cancer.